Tools

LEADER 03656cam 2200565 i 4500

001 on1393979978;

003 OCoLC;

005 20231106090930.0;

006 m o d f ;

007 cr b|||||a||||;

008 230816s2023 dcu ob f000 0 eng c;

024 8 a| 52-724q| (GPO jacket number);

035 a| (Sirsi) o1393979978;

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

074 a| 1019-C-01 (online);

086 0 a| Y 4.C 73/8:117-47;

088 a| Serial no. 117-47 (United States. Congress. House. Committee on Energy and Commerce);

245 14 a| The path forward :b| advancing treatments and cures for neurodegenerative diseases : hybrid hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventeenth Congress, first session, July 29, 2021.;

246 30 a| Advancing treatments and cures for neurodegenerative diseases;

264 1 a| Washington :b| U.S. Government Publishing Office,c| 2023.;

300 a| 1 online resource (vi, 277 pages);

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

500 a| In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).;

500 a| Associated bill citation(s): H.R. 3; H.R. 19; H.R. 2050; H.R. 3085.;

500 a| "Serial no. 117-47.";

500 a| GPO Cataloging Record Distribution Program (CRDP).;

504 a| Includes bibliographical references.;

511 0 a| Hearing witnesses: Richard J. Hodes, M.D., Director, National Institute on Aging, National Institutes of Health; Walter J. Koroshetz, M.D., Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health; Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services; Answers to submitted questions \2\ Merit Cudkowicz, M.D., Chair, Department of Neurology, and Director, Sean M. Healy and AMG Center for ALS, Massachusetts General Hospital; Cartier Esham, Ph.D., Chief Scientific Officer, Biotechnology Innovation Organization; Jinsy Andrews, M.D., Director of Neuromuscular Clinical Trials, Columbia University; Brian Wallach and Sandra Abrevaya, Cofounders, I AM ALS; Yvonne Latty, Caregiver; Kala Booth, Huntington's Disease Patient and Caregiver.;

518 a| Date of hearing: 2021-07-29.;

588 a| Description based on online resource, PDF version; title from title page (GovInfo, viewed Aug. 16, 2023).;

650 0 a| Nervous systemx| Degenerationz| United States.=| ^A6199;

650 0 a| Amyotrophic lateral sclerosisx| Treatmentz| United States.=| ^A148541;

650 0 a| Alzheimer's diseasex| Treatmentz| United States.=| ^A12721;

650 7 a| Health.2| cgpa;

655 7 a| Legislative hearings.2| lcgft;

776 08 i| Print version:a| United States. Congress. House. Committee on Energy and Commerce.t| Path forwardw| (OCoLC)1393979515;

856 40 u| https://purl.fdlp.gov/GPO/gpo2156027| 0;

922 a| BIBCONEWb| 20230816;

949 a| Click on web addressw| asish| joyner94;

596 a| 1;

998 a| 6235122;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6235122-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 9/15/2023x| EDOCUMENTz| JERESOURCE;

The path forward : advancing treatments and cures for neurodegenerative diseases : hybrid hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventeenth Congress, first session, July 29, 2021.

Author/creator	United States
Format	Electronic
Publication	Washington : U.S. Government Publishing Office, 2023.
Description	1 online resource (vi, 277 pages)
Supplemental Content	https://purl.fdlp.gov/GPO/gpo215602
Subjects	Nervous system--Degeneration. --United States. Nervous system--Diseases. --Treatment. --United States. Nervous system--Degeneration. --Treatment. --United States. Amyotrophic lateral sclerosis--Treatment. --United States. Alzheimer's disease--Treatment. --United States.

Portion of title	Advancing treatments and cures for neurodegenerative diseases
General note	In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).
General note	Associated bill citation(s): H.R. 3; H.R. 19; H.R. 2050; H.R. 3085.
General note	"Serial no. 117-47."
General note	GPO Cataloging Record Distribution Program (CRDP).
Bibliography note	Includes bibliographical references.
Performer	Hearing witnesses: Richard J. Hodes, M.D., Director, National Institute on Aging, National Institutes of Health; Walter J. Koroshetz, M.D., Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health; Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services; Answers to submitted questions \2\ Merit Cudkowicz, M.D., Chair, Department of Neurology, and Director, Sean M. Healy and AMG Center for ALS, Massachusetts General Hospital; Cartier Esham, Ph.D., Chief Scientific Officer, Biotechnology Innovation Organization; Jinsy Andrews, M.D., Director of Neuromuscular Clinical Trials, Columbia University; Brian Wallach and Sandra Abrevaya, Cofounders, I AM ALS; Yvonne Latty, Caregiver; Kala Booth, Huntington's Disease Patient and Caregiver.
Date/time/place of a event note	Date of hearing: 2021-07-29.
Source of description	Description based on online resource, PDF version; title from title page (GovInfo, viewed Aug. 16, 2023).
Issued in other form	Print version: United States. Congress. House. Committee on Energy and Commerce. Path forward
Genre/form	Legislative hearings.
Standard identifier#	52-724 (GPO jacket number)
Technical rpt number	Serial no. 117-47 (United States. Congress. House. Committee on Energy and Commerce)
GPO item number	1019-C-01 (online)
Govt. docs number	Y 4.C 73/8:117-47

The path forward : advancing treatments and cures for neurodegenerative diseases : hybrid hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventeenth Congress, first session, July 29, 2021.

Click here for more information about this title